VEGF Modulates Angiogenesis and Osteogenesis in Shockwave-Promoted Fracture Healing in Rabbits

Wang, Ching‐Jen; Huang, Ko-En; Sun, Yi-Chih; Yang, Yu Liang; Ko, Jih‐Yang; Weng, Li‐Chueh; Wang, Feng‐Sheng

doi:10.1016/j.jss.2010.01.045

Cited by 60 publications

(53 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, immunohistochemical analysis of the injured brain showed significantly lower expression of vWF but higher expression of VEGF in the treatment group than in the control group. This result indicated that bevacizumab has a strong effect on decreasing the number of vessels, consistent with a previous study [32] . However, other cancer studies [33][34] differ from ours, in that bevacizumab was reported to reduce the high expression of VEGF.…”

Section: Discussionsupporting

confidence: 93%

Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury

Dong

Song

et al. 2014

Neurosci. Bull.

View full text Add to dashboard Cite

To evaluate the effect of bevacizumab on cerebral ischemia, we used 2-deoxy-2-18 F-fluoro-D-glucose ( 18 F-FDG) small-animal positron emission tomography (PET) in the middle cerebral artery occlusion (MCAO) rat model. After baseline neurologic function tests and PET studies, MCAO Sprague-Dawley rats received bevacizumab or normal saline (controls). Weekly PET imaging and neurologic function tests showed that the 18 F-FDG accumulation in the bevacizumab group was similar to that in the controls during the fi rst 2 weeks, but lower than in controls at weeks 3 and 4. However, no difference was found in neurological scores between the groups. The number of von Willebrand factor-positive cells in the bevacizumab group was lower than that in controls. The expression of vascular endothelial growth factor was higher than in controls at week 4. These results suggested that bevacizumab does not infl uence functional recovery in this model of cerebral ischemia during a 4-week period, but inhibits vascular formation and metabolic recovery, which may be considered in cancer patients with a recent ischemic stroke.

show abstract

Section: Discussionsupporting

confidence: 93%

Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury

Dong

Song

et al. 2014

Neurosci. Bull.

View full text Add to dashboard Cite

show abstract

“…At the same time, it inhibits chondrogenesis and proliferation of osteoblastic progenitor cells. Consistent with our data are previous studies showing that bone repair and regeneration is inhibited when extracellular VEGF levels are reduced by adding the decoy receptor sVEGFR1 (sFlt1) or VEGF neutralizing antibodies (14,41). However, the rescue experiments with delivery of recombinant VEGF to the defect site in this study indicate that these effects of extracellular VEGF are dose dependent; high levels of VEGF inhibit infiltration of regenerative cells and osteoinduction of mesenchymal progenitors, resulting in decreased bone formation.…”

Section: Discussionsupporting

confidence: 92%

Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair

Hu¹,

Olsen²

2016

Journal of Clinical Investigation

492

396

View full text Add to dashboard Cite

“…An increase in VEGF is an indication of increased vascular permeability and microvascular activity, including angiogenic growth of new blood vessels. ESWT-promoted bone healing was associated with significant elevations of VEGF and angiogenesis and osteogenesis growth factors, whereas, inhibition of VEGF attenuated the effects of ESWT and decreased angiogenesis and osteogenesis factors [19].…”

Section: Discussionmentioning

confidence: 90%

“…Other studies have focused on the role of shock waves in inducing neovascularization and increasing of angiogenesis and osteogenesis related growth factors, such as eNOS (endothelial nitric oxide synthase), VEGF, PCNA (proliferating cell nuclear antigen) and BMP-2 (bone morphogenic protein 2) [19]. ESW may modulate endogenous NO production either under normal or inflammatory conditions.…”

Section: Discussionmentioning

confidence: 99%

Extracorporeal Shock Waves in the Treatment of Equinovarus Foot in a Duchenne Patient: A Case Report

Barazzuol¹,

Lampropoulou²,

Meneghini³

et al. 2015

J Nov Physiother Phys Rehabil

View full text Add to dashboard Cite

Background: Duchenne muscular dystrophy (DMD) is characterized by a progressive muscular weakness, with loss of independent ambulation. When the disease results in the complete loss of ambulation, one of the purposes of treatment during the latest phase is to prevent or reduce complications such as foot deformities.A 20-year-old DMD patient had a complete loss of muscular strength in the inferior and superior limbs and a severe bilateral clubfoot deformity. Active movements were not possible, while passive motion was very limited in dorsiflexion and pronation, inversion and eversion, with stronger limitation on the right foot.First, the patient was treated with gentle manipulation and casting for two weeks, but no improvement in passive range of motion was detected.The treatment was then modified by adding a session of focused extracorporeal shock wave therapy for five consecutive weeks. Results:After five shock wave sessions, both limbs showed a bilateral correction of the talometatarsal angle, respectively 26° on the right and 19° on the left foot. The most relevant improvements were estimated in the passive dorsiflexion of both ankles: with a gentle manipulation, both feet could return to the anatomical position, in such a way to allow the patient to wear his own shoes. Conclusions:There is increasing evidence that nitric oxide (NO) and vascular endothelial growth factor (VEGF) dysregulation is involved in DMD progression; on the other hand, extracorporeal shock wave therapy (ESWT) induces NO and VEGF production, thus promoting angiogenesis, and has proven effective in reducing muscular hypertone. ESWT shows a potential role in the treatment of Duchenne complications such as foot deformities, as part of a multidisciplinary rehabilitation program.of their antagonist muscle tendons 6 . When ambulation is no longer possible, the rehabilitation program focuses on the prevention or reduction of complications and deformities, in order to alleviate pain and pressure, to allow the patient to wear shoes, and to correctly place the feet on wheelchair footrests [7].Despite the absence of a specific treatment, the natural history of the DMD can be in part modified [1].Since the surgical therapy showed controversial results on long term effectiveness, there has been a growing consideration on the conservative approach, including drugs and rehabilitation. Nevertheless, in most studies the rehabilitation programme includes stretching, eccentric and aerobic exercise, sub maximum strengthening activity when residual strength is higher, while few authors emphasize the role of physical energies, like whole-body vibration [8,9] and laser therapy [10].Extracorporeal shock wave therapy (ESWT) is a relatively recent method used in the treatment of many musculoskeletal disorders, such as tendinopathies and non-union fractures.Over the past few years, ESWT has received a widespread consensus in many other fields, including in the treatment of spastic hypertone in patients affected by stroke: even a single session of shock

show abstract

VEGF Modulates Angiogenesis and Osteogenesis in Shockwave-Promoted Fracture Healing in Rabbits

Cited by 60 publications

References 27 publications

Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury

Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury

Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair

Extracorporeal Shock Waves in the Treatment of Equinovarus Foot in a Duchenne Patient: A Case Report

Contact Info

Product

Resources

About